BioSpace News Archive

Samsung Biologics (207940.KS) has entered into a service agreement with Panolos Bioscience to develop PB101, an Fc-fusion protein intended to treat solid tumors.

Phase 1 clinical trial for STI-1499 (COVI-GUARD™) in hospitalized COVID-19 patients has received FDA notice that it may proceed with patient enrollment.

- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the pricing of an upsized underwritten public offering of 3,300,000 shares of its common stock at a public offering price of $28.00 per share. 3,025,000 shares are being offered by 89bio, and 275,000 shares are being offered by a

PPD, Inc., a leading global contract research organization, announced the pricing of an underwritten public offering by certain stockholders of the Company, including stockholders affiliated with Hellman & Friedman LLC and The Carlyle Group Inc., of 38,000,000 shares of the Company’s common stock at a price to the public of $32.25 per share.

Searchlight Pharma is pleased to confirm the commercial availability in Canada of Addyi® (flibanserin) for the treatment of Hypoactive Sexual Desire Disorder (HSDD).

National Health Investors, Inc. provided a business update regarding its monthly contractual rent collections, deferral update, and average occupancy from its three largest senior housing operators.

Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, President and CEO, will present at the Singular Research Compelling Values 2020 Webinar on September 17, 2020 at 2:15 p.m. ET. The presentation will be available online via a webinar. To listen to the live webcast, please register with Singular Research at https://www.singularresearch.com/index.php/en/ A slide presentation that will be referenced during the webcast

Updated COVID-19 case projections released by PolicyLab at Children’s Hospital of Philadelphia forecast a stable or improving situation over the next four weeks for most of the counties that the model follows, including across the Midwest and Mid-Atlantic where case counts and test positivity rates had been high for some time.

Heartland Dental announced the affiliation of its first supported dental practice in Idaho. Craig R. Smith, DDS, of A Reason to Smile in Boise, joins over 1,700 dentists in more than 1,000 practices, who also benefit from the support of Heartland Dental.

Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Jeff Goater, its chief executive officer, and Robert Ross, M.D., its chief medical officer, will participate in the upcoming Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 21, where they will discuss Surface Oncology’s lead programs, SRF6